Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma

Overview of attention for article published in Endocrine-Related Cancer, January 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 31,028 followers.

RT @EndoCancer: Camilo Jimenez (@MDAndersonNews) et al. present the biomarker response dataset from a pivotal trial evaluating the efficacy…

Camilo Jimenez (@MDAndersonNews) et al. present the biomarker response dataset from a pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 meta-iodobenzylguanidine in patients with advanced #pheochromocytoma or #paraganglioma…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.